A detailed history of Hudson Canyon Capital Management transactions in Biogen Inc. stock. As of the latest transaction made, Hudson Canyon Capital Management holds 8,025 shares of BIIB stock, worth $1.4 Million. This represents 1.26% of its overall portfolio holdings.

Number of Shares
8,025
Previous 7,700 4.22%
Holding current value
$1.4 Million
Previous $1.66 Billion 12.05%
% of portfolio
1.26%
Previous 1.07%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024

BUY
$190.52 - $236.72 $61,919 - $76,934
325 Added 4.22%
8,025 $1.86 Billion
Q3 2023

Nov 14, 2023

BUY
$253.3 - $285.89 $730,770 - $824,792
2,885 Added 59.92%
7,700 $1.98 Billion
Q2 2023

Aug 02, 2023

SELL
$275.25 - $318.06 $42,113 - $48,663
-153 Reduced 3.08%
4,815 $1.37 Billion
Q1 2023

Aug 02, 2023

BUY
$256.56 - $292.34 $248,350 - $282,985
968 Added 24.2%
4,968 $1.38 Billion
Q4 2022

Aug 02, 2023

BUY
$252.44 - $306.72 $315,550 - $383,400
1,250 Added 45.45%
4,000 $1.11 Billion
Q3 2022

Aug 02, 2023

BUY
$194.69 - $268.46 $535,397 - $738,265
2,750 New
2,750 $734 Million
Q2 2022

Aug 02, 2023

SELL
$187.54 - $223.02 $1.13 Million - $1.34 Million
-6,027 Closed
0 $0
Q4 2021

Aug 02, 2023

SELL
$223.92 - $287.77 $66,728 - $85,755
-298 Reduced 4.71%
6,027 $1.45 Billion
Q2 2021

Aug 02, 2023

SELL
$259.0 - $414.71 $6,475 - $10,367
-25 Reduced 0.39%
6,325 $2.19 Billion
Q1 2021

Aug 02, 2023

BUY
$242.95 - $284.63 $128,034 - $150,000
527 Added 9.05%
6,350 $1.78 Billion
Q4 2020

Aug 02, 2023

BUY
$236.26 - $355.63 $1.38 Million - $2.07 Million
5,823 New
5,823 $1.43 Billion

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $25.1B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Hudson Canyon Capital Management Portfolio

Follow Hudson Canyon Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hudson Canyon Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Hudson Canyon Capital Management with notifications on news.